Interestingly, resistance mechanisms to oncological drugs based on drug‐efflux, cell apoptosis, autophagy, and cancer cell stemness, as well as, mutations in TK receptors (e.g. EGFR) have partially been explained for both chemotherapy and targeted therapy in lung cancer [41, 42]. This evidence concerns the gene EGFR and lung cancer.